Russell B. Smith

Russell B. Smith

Auto-generated profile, based on publicly available information

Russell B. Smith

Department of Otolaryngology, University of Iowa, Iowa city, IA 52242, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2004 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
GFGerry F. Funk
Gerry F. Funk
LKLucy H. Karnell
Lucy H. Karnell
RSRussell B. Smith
Russell B. Smith
ACAlan J. Christensen
Alan J. Christensen
An increased awareness of the need to incorporate health-related quality-of-life (HRQOL) information into the outcome assessment of patients with head and neck cancer (HNC) has been demonstrated by the number of recent publications addressing this issue and by a recent international conference devoted to the measurement and reporting of quality of life in HNC held in McLean, Va, in October 2002. The HRQOL outcomes are particularly important in HNC management because the various treatment modalities may offer equivalent survival but potentially different HRQOL outcomes.1 There are currently a variety of validated, HNC disease-specific quality-of-life surveys in use.2 As the use of these instruments in clinical practice and research increases, and as HRQOL scores are more frequently reported as clinical outcomes in the literature, it will be important for clinicians and researchers to be able to interpret these scores in a clinically useful way. For that to happen, two fundamental conditions must be met. First, data must be presented in formats that are clinically meaningful. The comparison of mean HRQOL scores representing abstract domains of health functioning rarely imparts a clinically useful message. Second, the magnitude of clinically significant intragroup changes or intergroup differences in HRQOL scores needs to be determined and reported. The simple reporting of a difference in HRQOL scores between 2 groups of patients rarely gives the clinician information that can be acted on.

1 July 2003 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
RSRussell B. Smith
Russell B. Smith
RTRobert D. Thomas
Robert D. Thomas
GFGerry F. Funk
Gerry F. Funk
MICROVASCULAR FREE tissue transfer is commonly used today for reconstruction of complex head and neck defects. Many options exist for transfer of free vascularized bone for reconstruction of segmental mandibular and maxillary defects, with the fibula free flap being commonly used in these settings. Many potentially complicating factors must be evaluated when considering a fibula free flap harvest. The potential compromise of lower extremity vascularity associated with flap harvest, the presence of atherosclerotic disease in the peroneal vessel that could complicate anastomosis, and the presence of aberrant vascular anatomy in the lower extremities should be excluded. Consequently, preoperative assessment of lower extremity vascular anatomy should be performed to identify high-risk flap candidates before the fibula free flap is harvested.

7 January 2003 in Head & Neck
Verified
Journal Article
Closed access
PDF file
RSRussell B. Smith
Russell B. Smith
GFGerry F. Funk
Gerry F. Funk

12 December 2006 in Head & Neck
Verified
Journal Article
Closed access
PDF file
RSRussell B. Smith
Russell B. Smith
DHDouglas K. Henstrom
Douglas K. Henstrom
LKLucy H. Karnell
Lucy H. Karnell
KCKristi C. Chang
Kristi C. Chang
DGDavid P. Goldstein
David P. Goldstein
GFGerry F. Funk
Gerry F. Funk

1 October 2007 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
RSRussell B. Smith
Russell B. Smith

1 September 2005 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
RSRussell B. Smith
Russell B. Smith
There is little doubt that concurrent CRT has a valuable role in the management of advanced-stage laryngeal carcinoma. The results of both the VA laryngeal trial as well as the RTOG 91-11 trial have given us great insight into the utility of CRT in the management of this disease.1,2 Enepekides has thoroughly reviewed the pertinent literature on the use of both partial laryngeal surgery and CRT for advanced-stage laryngeal carcinoma.